Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer's disease mouse model

Alzheimer's Research and Therapy

Volumn 7, Issue 1, 2015, Pages

  Nygaard, Haakon B ^a,b   Kaufman, Adam C ^a   Sekine Konno, Tomoko ^a   Huh, Linda L ^a,c   Going, Hilary ^a   Feldman, Samantha J ^a   Kostylev, Mikhail A ^a   Strittmatter, Stephen M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BRIVARACETAM; ETHOSUXIMIDE; ETIRACETAM; PHENYTOIN; PROTEIN; SYNAPTIC VESICLE PROTEIN 2A; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ELECTRODE; ELECTROENCEPHALOGRAPHY; EPILEPTIC DISCHARGE; FEMALE; LOADING DRUG DOSE; LONG TERM MEMORY; MALE; MEMORY DISORDER; MORRIS WATER MAZE TEST; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; SPATIAL MEMORY; SPIKE WAVE; SYNAPSE; TONIC CLONIC SEIZURE;

EID: 84928716471     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-015-0110-9     Document Type: Article

References (28)

1. Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009;66:435-40.
2. Scarmeas N, Honig LS, Choi H, Cantero J, Brandt J, Blacker D, et al. Seizures in Alzheimer disease: who, when, and how common? Arch Neurol. 2009;66:992-7.
3. Irizarry MC, Jin S, He F, Emond JA, Raman R, Thomas RG, et al. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol. 2012;69:368-72.
4. Palop J, Chin J, Roberson E, Wang J, Thwin M, Bien-Ly N, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697-711.
5. Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fülöp L, et al. Amyloid β-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009;29:3453-62.
6. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, et al. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci. 2012;15:1227-35.
7. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A. 2012;109:E2895-903.
8. Shi JQ, Wang BR, Tian YY, Xu J, Gao L, Zhao SL, et al. Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice. CNS Neurosci Ther. 2013;19:871-81.
9. Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74:467-74.
10. Bomben V, Holth J, Reed J, Cramer P, Landreth G, Noebels J. Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy. Neurobiol Aging. 2014;35:2091-5.
11. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, et al. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci. 2011;31:700-11.
12. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Laurén J, Gimbel ZA, et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci. 2010;30:6367-74.
13. Jankowsky J, Fadale D, Anderson J, Xu G, Gonzales V, Jenkins N, et al. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase. Hum Mol Genet. 2004;13:159-70.
14. Oddo S, Caccamo A, Shepherd J, Murphy M, Golde T, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron. 2003;39:409-21.
15. Morris RGM. Spatial localization does not require the presence of local cues. Learn Motiv. 1981;12:239-60.
16. Kashiwaya Y, Bergman C, Lee JH, Wan R, King MT, Mughal MR, et al. A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. Neurobiol Aging. 2013;34:1530-9.
17. el Sayed MA, Löscher W, Frey HH. Pharmacokinetics of ethosuximide in the dog. Arch Int Pharmacodyn Ther. 1978;234:180-92.
18. Ziyatdinova S, Gurevicius K, Kutchiashvili N, Bolkvadze T, Nissinen J, Tanila H, et al. Spontaneous epileptiform discharges in a mouse model of Alzheimer's disease are suppressed by antiepileptic drugs that block sodium channels. Epilepsy Res. 2011;94:75-85.
19. Ichimiya Y, Emson PC, Mountjoy CQ, Lawson DE, Heizmann CW. Loss of calbindin-28 K immunoreactive neurones from the cortex in Alzheimer-type dementia. Brain Res. 1988;475:156-9.
20. Dutar P, Potier B, Lamour Y, Emson PC, Senut MC. Loss of calbindin-28 K immunoreactivity in hippocampal slices from aged rats: a role for calcium? Eur J Neurosci. 1991;3:839-49.
21. Carter DS, Harrison AJ, Falenski KW, Blair RE, DeLorenzo RJ. Long-term decrease in calbindin-D28K expression in the hippocampus of epileptic rats following pilocarpine-induced status epilepticus. Epilepsy Res. 2008;79:213-23.
22. Frankel WN, Beyer B, Maxwell CR, Pretel S, Letts VA, Siegel SJ. Development of a new genetic model for absence epilepsy: spike-wave seizures in C3H/He and backcross mice. J Neurosci. 2005;25:3452-8.
23. Ellens DJ, Hong E, Giblin K, Singleton MJ, Bashyal C, Englot DJ, et al. Development of spike-wave seizures in C3H/HeJ mice. Epilepsy Res. 2009;85:53-9.
24. Evason K, Huang C, Yamben I, Covey DF, Kornfeld K. Anticonvulsant medications extend worm life-span. Science. 2005;307:258-62.
25. Collins JJ, Evason K, Pickett CL, Schneider DL, Kornfeld K. The anticonvulsant ethosuximide disrupts sensory function to extend C. elegans lifespan. PLoS Genet. 2008;4:e1000230.
26. Shen H, Zhang B, Shin JH, Lei D, Du Y, Gao X, et al. Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007;226:52-60.
27. Liedorp M, Stam CJ, van der Flier WM, Pijnenburg YA, Scheltens P. Prevalence and clinical significance of epileptiform EEG discharges in a large memory clinic cohort. Dement Geriatr Cogn Disord. 2010;29:432-7.
28. Vossel KA, Beagle AJ, Rabinovici GD, Shu HD, Lee SE, Naasan G, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013;70:1158-66.